Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 71
6.385,31 S&P · 17,80 Vola-Index · 117.722,51 BTC · 1,14687 EURUSD
System-State: Number of processed items 53.724 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
FR0010331421
State: 30.07.2025 | 12PM
Do you already know our new terminal view? Click here.
FIGI: BBG000Q71CK5
IPH
Innate Pharma
GICS: 35201010 · Sector: EQTY · Sub-Sector: -
NAME
Innate Pharma
ISIN
FR0010331421
TICKER
IPH
MIC
XPAR
REUTERS
IPH.PA
BLOOMBERG
IPH FP
Tue, 29.07.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the company’s CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. BTIG, a global financial services firm specializing in investment banking,...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Fri, 04.07.2025       Innate Pharma
FR0010331421

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as wel...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 17.06.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will participate in the upcoming investor conferences, detailed below. H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference Dates: June 24, 2025 | Virtual Wolfe Research Virtual ...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Fri, 13.06.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of preclinical data for IPH6501, its proprietary ANKET® targeting CD20 currently under investigation in a Phase 1/2 study in relapsed and/or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT06088654), at the ...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 27.05.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the upcoming investor conferences, detailed below. Jefferies Global Healthcare Conference Dates: June 3 – 5 2025 | New York, USA The executive team will part...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Fri, 23.05.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted. A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Fri, 23.05.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the presentation of long-term follow-up data from the Phase 2 TELLOMAK clinical trial evaluating lacutamab, an anti-KIR3DL2 monoclonal antibody, in patients with Sézary syndrome (SS) and mycosis fungoides (MF), two rare and aggressive...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 19.05.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that four abstracts with Innate’s drugs in clinical development have been accepted for the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place May 30-June 3, 2025 in Chicago, Illinois. “We are looking forwa...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Thu, 15.05.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place ...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 13.05.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the quarter ending March 31, 2025. “The first quarter of 2025 was marked by significant progress across both our pipeline and strategic partnerships,” said Jonathan Dickinson, Chief Executive Off...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Mon, 12.05.2025       Innate Pharma
FR0010331421

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 06.05.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Tuesday, May 13, 2025, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progress during the first quarter of 2025. In addition, members of the executive management team will ...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 30.04.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2024 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2024 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 30, 2025. It can be...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Tue, 29.04.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2025...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.04.2025       Innate Pharma
FR0010331421

Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Thu, 24.04.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces a €14,999,998.59 capital increase subscribed by Sanofi. As announced on April 23, 2025, and given the satisfactory market conditions, Sanofi has agreed to subscribe to 8,345,387 new ordinary shares of Innate, at a price of €1.7974 pe...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 23.04.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January 2016 Research Collaboration and License Agreement (the “2016 Agreement”) with Sanofi: As previously disclosed and in alignment with its current strategic priorities, Sanofi will opt to pursue the development o...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 16.04.2025       Innate Pharma
FR0010331421

Regulatory News:  Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will hold its annual general meeting of shareholders (“AGM”) at 10:30 a.m. CEST on May 22, 2025 in its headquarters, 117 avenue de Luminy, 13009 Marseille. The Notice of Meeting of this AGM was published on April 16, 2025 in the French legal bullet...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Wed, 16.04.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced it will propose to its Annual General Meeting taking place on May 22, 2025, to move from an executive board/supervisory board corporate governance structure to one with a CEO/board of directors. This transformation is part of the Comp...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Thu, 03.04.2025       Innate Pharma
FR0010331421

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Stifel 2025 Virtual Targeted Oncology Forum being held on April 8 – 9, 2025. The executive team will participate in a fireside chat scheduled on Wednesday, ...
Read More
Innate Pharma
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Fiserv
FISERV INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Fiserv, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FI
© BusinessWire
Information Services Group
U.K. Firms Seek Integrated Cybersecurity Approach
© BusinessWire
dynaCERT
dynaCERT Appoints John Amodeo as Director, Expanding Global Sales Strategy
© BusinessWire
U.S. Bancorp
U.S. Bank Marks 25 Years in Europe with Spotlight on Irish Origins, Innovation and Community Leadership
© BusinessWire
Viridian Therapeutics
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
© BusinessWire
Interactive Brokers
Interactive Brokers Expands Forecast Contracts to European Market
© BusinessWire
Piraeus Financial
Piraeus Financial Holdings: First Half 2025 Financial Results
© BusinessWire
Takeda Pharmaceutical
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression
© BusinessWire
Rio Tinto
Rio Tinto: Very resilient financial results as we grow and diversify our portfolio
© BusinessWire
Evercore
Evercore to Acquire Robey Warshaw, a Leading UK-Based Independent Advisory Firm
© BusinessWire
Primerica
Primerica Household Budget Index™ Data: Middle-Income Purchasing Power Held Steady in June
© BusinessWire
Faraday Future
Faraday Future to Present at the J.P. Morgan Auto Investor Conference in New York on August 12, 2025
© BusinessWire
SoFi Technologies
SoFi Technologies, Inc. Announces Pricing of Public Offering of Common Stock
© BusinessWire
Lockheed Martin
LMT Investors Have Opportunity to Lead Lockheed Martin Corporation Securities Fraud Lawsuit with the Schall Law Firm
© BusinessWire
BBB Foods
TBBB Invites You to Join Its Second Quarter 2025 Earnings Conference Call
© BusinessWire
Interactive Brokers
Interactive Brokers Launches NISA Accounts to Help Japanese Investors Build Wealth Tax-Free
© BusinessWire
PBCO Financial
PBCO Financial Corporation Reports Second Quarter 2025 Results
© BusinessWire
First Northern
First Northern Community Bancorp Reports Second Quarter 2025 Net Income of $5.5 Million
© BusinessWire
B&G Foods
B&G Foods Declares Regular Quarterly Dividend
© BusinessWire
Sierra Metals
Sierra Metals Announces Results of 2025 Annual General and Special Meeting Including Approval of the Second-Step Acquisition of Sierra Metals by Alpayana
© BusinessWire
Compass Minerals
Compass Minerals Announces Conference Call to Discuss Third-Quarter Fiscal 2025 Results
© BusinessWire
Citizens Holding
Citizens Holding Company Reports Earnings
© BusinessWire
Delek Logistics
Delek Logistics Partners, LP Increases Quarterly Cash Distribution to $1.115 per Common Limited Partner Unit
© BusinessWire
AST SpaceMobile
AST SpaceMobile Announces Closing of Private Offering of $575.0 Million of Convertible Senior Notes Due 2032
© BusinessWire
MaxLinear
MaxLinear, Inc. Announces Third Quarter 2025 Financial Conference Participation
© BusinessWire

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S